These results thus show that homo-versus heterozygous SETD2 loss have not the same impact on leukemogenesis and suggest that SETD2 may function as an haplo-insufficient tumor suppressor and that homozygous loss of SETD2 hamper cancer progression. The gene discussed is SETD2; the disease is neoplasm.